SEC Form 4

Instruction 1(b)

[]

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287										
Estimated average burden										
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

		l l								7										
1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol MERIT MEDICAL SYSTEMS INC I MASI								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Gunderson Thomas James							MERIT MEDICAL SYSTEMS INC [MMSI								r	10% Owner				
(Last) (First) (Middle)						J 3. Date of Earliest Transaction (Month/Day/Year) 03/04/2024								Officer below)	(give title	e Other (specify below)		specify		
1600 WEST MERIT PARKWAY							4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street)														Line)						
SOUTH														X Form filed by One Reporting Person Form filed by More than One Reporting						
JORDAN UT 84095														Person						
(City) (State) (Zip)					_ R	Rule 10b5-1(c) Transaction Indication														
							Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tal	ble I - N	on-Dei	rivativ	ve Se	ecuri	ties Ac	quire	d, Di	sposed o	f, or Be	neficially	v Owned						
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day/						Execution Dat		on Date,	3. Transaction Code (Instr. 8)				cquired (A) or D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following			7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)		
Common	Stock, No	Par Value		03/04	4/2024	024		М		25,000	Α	\$34.4	37	,414		D				
Common Stock, No Par Value 03/04/20					4/2024	024		S		18,157	D	\$76.032 ⁽⁾) 19	,257		D				
			Table II								posed of, convertik			Owned						
1. Title of Derivative Security (Instr. 3)	of 2. 3. Transaction 3A. Deemed 4. tive Conversion Date Execution Date, Transaction if any C				ansaction of ode (Instr. Derivative					of Securi Underlyir	ng e Security	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s illy g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)				
			Code		v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares								
Non- qualified stock options (right to buy)	\$34.4	03/04/2024			М			25,000	05/24/2	018 ⁽²⁾	05/24/2024	Common Stock	25,000	\$0	0		D			
Non- qualified stock options (right to buy)	\$50.5								06/07/2	019 ⁽³⁾	06/07/2025	Common Stock	25,000		25,00	0	D			
Non- qualified stock options (right to buy)	\$52.17								05/24/2	020 ⁽⁴⁾	05/24/2026	Common Stock	13,750		13,75	0	D			
Non- qualified stock options (right to buy)	\$52.17								05/31/2	020 ⁽⁵⁾	05/31/2026	Common Stock	7,500		7,500)	D			

Explanation of Responses:

1. The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$76.00 to \$76.25, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

2. Becomes exercisable in equal annual installments of 20% commencing 05/24/2018.

3. Becomes exercisable in equal annual installments of 20% commencing 06/07/2019.

4. Becomes exercisable in equal annual installments of 33% commencing 05/24/2020.

5. Becomes exercisable in equal annual installments of 33% commencing 05/31/2020.

/s/ Brian G. Lloyd, Attorney-in-Fact 03/05/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.